Behaviour change is set to become a key skill for pharma companies in the very near future – an essential beyond-the-pill strategy, often delivered via digital tech, that can help keep peop
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh